Targeting Angiogenesis and Tumor Microenvironment in Metastatic Colorectal Cancer: Role of Aflibercept

Table 1

Bevacizumab, aflibercept, and regorafenib are antiangiogenic drugs currently approved for mCRC treatment. These drugs have proved successful for the clinical treatment of various types of cancer and their mechanism of action results different affecting a variable range of cell types and signaling within tumor microenvironment.

Drug	Indication	Mechanism of action
Bevacizumab	First-/second-line mCRC plus CT	MoAb binding VEGF-A
Aflibercept	Second-line mCRC plus FOLFIRI	VEGF decoy binding VEGF-A, VEGF-B, and PlGF
Regorafenib	Third-line mCRC as single agent	Multikinase inhibitor of RTKI of VEGFR-2 and -3, TIE-2, PDGFR, FGFR, RET, and c-kit